{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:21:05Z","timestamp":1793154065225,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n Methamphetamine use disorder is a global health challenge for which there are no approved pharmacotherapies. The safety and effectiveness of mirtazapine, a promising candidate for methamphetamine use disorder, has not been established in routine clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the safety and effectiveness of mirtazapine as a pharmacotherapy for methamphetamine use disorder in routine clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase 3, parallel-group, double-blind, placebo-controlled randomized clinical trial was conducted between November 16, 2022, and May 1, 2025, at 6 outpatient alcohol and other drug clinics in Australia among adults with moderate to severe methamphetamine use disorder. Data analysis was conducted from May to September 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Mirtazapine (30 mg daily for 12 weeks) or equivalent placebo.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the change in days of methamphetamine use in the past 28 days from baseline to week 12. Secondary end points were depression, insomnia, HIV risk behavior, quality of life, and methamphetamine-negative oral fluid samples.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 344 participants randomized, 339 participants received the intervention (167 in the placebo group and 172 in the mirtazapine group). Mean (SD) age was 42.0 (8.6) years, 126 participants (37.2%) were female, and participants had used methamphetamine for a median (IQR) of 24 days (17-28) of the past 28 days at baseline. The mean reduction in days of methamphetamine use from baseline to week 12 was greater in the mirtazapine group (7.0 days of 28 days) than in the placebo group (4.8 days of 28 days; mean difference, 2.2 days; 95% CI, \u22124.2 to \u22120.2 days;\n P<\/jats:italic>\n \u2009=\u2009.02). More participants in the mirtazapine group reported drowsiness (47% vs 33%) and weight gain (10% vs 3%). Forty participants (23%) discontinued mirtazapine due to adverse events compared to 25 participants (15%) in the placebo group. No significant effects of mirtazapine on secondary end points were found.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this parallel-group randomized clinical trial, mirtazapine delivered in routine clinical practice reduced methamphetamine use in adults with methamphetamine use disorder. No unexpected safety concerns delivering mirtazapine in this setting were found; this finding has important clinical implications in the absence of any approved pharmacotherapies for methamphetamine use disorder.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n anzctr.org.au Identifier:\n ACTRN12622000235707<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.0159","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:32:02Z","timestamp":1775057522000},"page":"581","source":"Crossref","is-referenced-by-count":9,"title":["Mirtazapine for Methamphetamine Use Disorder"],"prefix":"10.1001","volume":"83","author":[{"given":"Rebecca","family":"McKetin","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Shoptaw","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Saunders","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Clare","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Prevention Research Collaboration, Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyna","family":"Turner","sequence":"additional","affiliation":[{"name":"The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"Dean","sequence":"additional","affiliation":[{"name":"The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia"},{"name":"Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kelly","sequence":"additional","affiliation":[{"name":"School of Psychology, Faculty of Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Arunogiri","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Koeijers","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayla J.","family":"Degan","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"School of Psychology, Faculty of Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farrell","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goodman-Meza","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reid","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cordaro","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hill","sequence":"additional","affiliation":[{"name":"The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia"},{"name":"Drug and Alcohol Services, Barwon Health, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lundin","sequence":"additional","affiliation":[{"name":"The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia"},{"name":"Drug and Alcohol Services, Barwon Health, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hayllar","sequence":"additional","affiliation":[{"name":"Biala, Metro North Health, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Christmass","sequence":"additional","affiliation":[{"name":"Next Step Community Alcohol and Drug Service, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Liaw","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica","family":"Liu","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Woods","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Drug and Alcohol Services of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaire","family":"Brewerton","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services of South Australia, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Holyoak","sequence":"additional","affiliation":[{"name":"Alcohol, Tobacco and Other Drugs Service, Townsville, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Tid-Fung","family":"Wu","sequence":"additional","affiliation":[{"name":"Alcohol, Tobacco and Other Drugs Service, Townsville, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Maher","sequence":"additional","affiliation":[{"name":"Alcohol, Tobacco and Other Drugs Service, Townsville, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noni","family":"O\u2019Dea","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Keygan","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Kontogiannis","sequence":"additional","affiliation":[{"name":"School of Psychology, Faculty of Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Palmer","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caity","family":"Morrison","sequence":"additional","affiliation":[{"name":"The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wrobel","sequence":"additional","affiliation":[{"name":"The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bec","family":"Hyland","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gift","family":"Kiden","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Romeo","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khine Wut Yee","family":"Kyaw","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Byrne","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Colledge-Frisby","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"National Drug Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Zahra","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[{"name":"The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia"},{"name":"Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Drug and Alcohol Services, Barwon Health, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10209","key":"yoi260009r1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","article-title":"Responding to global stimulant use: challenges and opportunities.","volume":"394","author":"Farrell","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"yoi260009r2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults.","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260009r3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14688","article-title":"Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.","volume":"1508","author":"Jones","year":"2022","journal-title":"Ann N Y Acad Sci"},{"issue":"15","key":"yoi260009r4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/jama.2025.13881","article-title":"More than half of US overdose deaths now involve stimulants.","volume":"334","author":"Anderer","year":"2025","journal-title":"JAMA"},{"issue":"12","key":"yoi260009r5","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/add.14755","article-title":"Pharmacotherapy for methamphetamine\/amphetamine use disorder-a systematic review and meta-analysis.","volume":"114","author":"Chan","year":"2019","journal-title":"Addiction"},{"issue":"2","key":"yoi260009r6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and naltrexone in methamphetamine use disorder.","volume":"384","author":"Trivedi","year":"2021","journal-title":"N Engl J Med"},{"key":"yoi260009r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109295","article-title":"Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: a systematic review and meta-analysis.","volume":"232","author":"Naji","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"yoi260009r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112769","article-title":"Mirtazapine reduces hypothetical methamphetamine demand in humans.","volume":"274","author":"Rush","year":"2025","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"yoi260009r9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.pharmthera.2012.08.013","article-title":"Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.","volume":"136","author":"Graves","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"3","key":"yoi260009r10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0304-3940(02)01033-9","article-title":"Methamphetamine increases the hippocampal a(2A)-adrenergic receptor and Galpha(o) in mice.","volume":"334","author":"Nishio","year":"2002","journal-title":"Neurosci Lett"},{"issue":"6","key":"yoi260009r11","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab001","article-title":"Methamphetamine and sleep impairments: neurobehavioral correlates and molecular mechanisms.","volume":"44","author":"Vrajov\u00e1","year":"2021","journal-title":"Sleep"},{"issue":"11","key":"yoi260009r12","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","article-title":"Mirtazapine to reduce methamphetamine use: a randomized controlled trial.","volume":"68","author":"Colfax","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"yoi260009r13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","article-title":"Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial.","volume":"77","author":"Coffin","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260009r14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s13063-024-08238-y","article-title":"A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial.","volume":"25","author":"McKetin","year":"2024","journal-title":"Trials"},{"key":"yoi260009r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"1","key":"yoi260009r17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","article-title":"The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties.","volume":"68","author":"Fals-Stewart","year":"2000","journal-title":"J Consult Clin Psychol"},{"issue":"9","key":"yoi260009r18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"6","key":"yoi260009r19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0022-3999(00)00095-7","article-title":"Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria.","volume":"48","author":"Soldatos","year":"2000","journal-title":"J Psychosom Res"},{"issue":"5","key":"yoi260009r20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1360-0443.1992.tb02719.x","article-title":"Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index.","volume":"87","author":"Darke","year":"1992","journal-title":"Br J Addict"},{"issue":"10","key":"yoi260009r21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"16","key":"yoi260009r23","first-page":"1","article-title":"Columbia-Suicide Severity Rating Scale screen version: initial screening for suicide risk in a psychiatric emergency department.","volume":"52","author":"Bjureberg","year":"2021","journal-title":"Psychol Med"},{"issue":"2","key":"yoi260009r24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA).","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"7","key":"yoi260009r25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/add.16730","article-title":"Lisdexamfetamine in the treatment of methamphetamine dependence: a randomised, placebo-controlled trial.","volume":"120","author":"Ezard","year":"2025","journal-title":"Addiction"},{"issue":"5","key":"yoi260009r26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/add.16409","article-title":"Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: findings from 13 multisite randomized clinical trials.","volume":"119","author":"Amin-Esmaeili","year":"2024","journal-title":"Addiction"},{"issue":"3","key":"yoi260009r27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamapsychiatry.2013.283","article-title":"Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.","volume":"70","author":"McKetin","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"yoi260009r28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/add.12474","article-title":"Does methamphetamine use increase violent behaviour? evidence from a prospective longitudinal study.","volume":"109","author":"McKetin","year":"2014","journal-title":"Addiction"},{"key":"yoi260009r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108178","article-title":"Antagonizing serotonin 2A (5-HT2A) receptors attenuates methamphetamine-induced reward and blocks methamphetamine-induced anxiety-like behaviors in adult male rats.","volume":"215","author":"Madden","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"yoi260009r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113521","article-title":"Blocking serotonin 2A (5-HT2A) receptors attenuates the acquisition of methamphetamine-induced conditioned place preference in adult female rats.","volume":"415","author":"Madden","year":"2021","journal-title":"Behav Brain Res"},{"issue":"3","key":"yoi260009r31","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.5694\/j.1326-5377.2011.tb03266.x","article-title":"Major depression among methamphetamine users entering drug treatment programs.","volume":"195","author":"McKetin","year":"2011","journal-title":"Med J Aust"},{"issue":"4","key":"yoi260009r32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/add.16714","article-title":"Anxiety and depression among a community-recruited cohort of people who use methamphetamine: a longitudinal analysis.","volume":"120","author":"Duncan","year":"2025","journal-title":"Addiction"},{"key":"yoi260009r33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.11.004","article-title":"Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.","volume":"158","author":"Kiluk","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"yoi260009r34","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/add.16200","article-title":"Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis.","volume":"118","author":"Bharat","year":"2023","journal-title":"Addiction"},{"issue":"3","key":"yoi260009r35","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/add.16085","article-title":"Diagnostic accuracy for self-reported methamphetamine use versus oral fluid test as the reference standard in a methamphetamine-dependent intervention trial population.","volume":"118","author":"Carter","year":"2023","journal-title":"Addiction"},{"key":"yoi260009r15","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"yoi260009r22","volume-title":"Columbia-Suicide Severity Rating Scale (C-SSRS) Version 6","author":"Posner","year":"2008"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2847070\/jamapsychiatry_mcketin_2026_oi_260009_1779900167.405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:00:29Z","timestamp":1780498829000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2847070"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0159","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}